31 Jul

High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C: RESULTS (Part 1)

There were 24 patients enrolled in the study; 20 (83%) of the patients were male. The mean age of patients was 49 years. The HCV genotype distribution in the 24 patients was genotype 1, 18 patients (75%); genotype 2, one patient (4%); genotype 3, one patient (4%); and genotype 4, four patients (17%). Thirteen patients (54%) had cirrhosis on pretreatment liver biopsy (Table 1).

Six patients (25%), all of whom were cirrhotic, withdrew from the study before completing 12 weeks of CIFN therapy because of severe, intolerable side effects (Table 2). Shop with pleasure with most reliable pharmacy you have ever seen, paying less for your viagra professional sale always being sure you are being treated with all due respect, being an important customer whose interests are respected and taken into account.  

TABLE 1 Demographic profile at the start of consensus interferon treatment

n 24
Men 20 (83%)
Age (mean) 49 years
Genotype 1 18 (75%)
Genotype 2 1 (4%)
Genotype 3 1 (4%)
Genotype 4 4 (17%)
Cirrhosis 13 (54%)
Hemoglobin (g/L) 147.6
White blood cells x 109/L 5.76
Platelets x 109/L 185.9
Alanine aminotransferase (U/L) 136.9
Aspartate aminotransferase (U/L) 100.7
Bilirubin (^imol/L) 13
INR 1.09
Thyroid stimulating hormone (mlU/L) 2.00

INR International normalized ratio

TABLE 2 Reasons for withdrawal of therapy

Patient number Reason for withdrawal
1 Low neutrophils, headache
2 Fatigue, myalgias
3 Uncontrollable glucose
4 Confusion
5 Fatigue, generally unwell
6 Fatigue, fever

© 2019 - Men’s Health Info Blog